Search Results - "Ikediobi, Ogechi"

Refine Results
  1. 1

    Eosinophilic cellulitis in response to BNT162b2 COVID‐19 vaccination by Ikediobi, Ogechi, Eichenfield, Dawn Z., Barrio, Victoria R.

    Published in Pediatric dermatology (01-09-2022)
    “…A 12‐year‐old boy presented with a 2‐week history of persistent pruritic edematous plaques one day after he received the first dose of the BNT162b2 COVID‐19…”
    Get full text
    Journal Article
  2. 2

    The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions by Marques, Sara Correia, Ikediobi, Ogechi N

    Published in Human genomics (01-04-2010)
    “…Over the past decade, the number of pharmacogenetic tests has increased considerably, allowing for the development of our knowledge of their clinical…”
    Get full text
    Journal Article
  3. 3

    Analysis of pharmacogenetic traits in two distinct South African populations by Ikediobi, Ogechi, Aouizerat, Bradley, Xiao, Yuanyuan, Gandhi, Monica, Gebhardt, Stefan, Warnich, Louise

    Published in Human genomics (01-05-2011)
    “…Our knowledge of pharmacogenetic variability in diverse populations is scarce, especially in sub-Saharan Africa. To bridge this gap in knowledge, we…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7

    Pharmacogenetics in dermatology: a patient-centered update by Comfere, Nneka I., Ikediobi, Ogechi N., Peters, Margot S., el-Azhary, Rokea A., Gibson, Lawrence E.

    Published in International journal of dermatology (01-08-2013)
    “…Background The term pharmacogenetics is used to describe an evolving field that aims to understand the relationship between individual variations in genetic…”
    Get full text
    Journal Article
  8. 8

    The clinical application of UGT1A1pharmacogenetic testing: Gene-environment interactions by Marques, Sara Correia, Ikediobi, Ogechi N

    Published in Human genomics (01-04-2010)
    “…Over the past decade, the number of pharmacogenetic tests has increased considerably, allowing for the development of our knowledge of their clinical…”
    Get full text
    Journal Article
  9. 9

    In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation by Ikediobi, Ogechi N, Reimers, Mark, Durinck, Steffen, Blower, Paul E, Futreal, Andrew P, Stratton, Michael R, Weinstein, John N

    Published in Molecular cancer therapeutics (01-06-2008)
    “…The panel of 60 human cancer cell lines (the NCI-60) assembled by the National Cancer Institute for anticancer drug discovery is a widely used resource. We…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12

    Pharmacogenomics of Allopurinol and Sulfamethoxazole/Trimethoprim: Case Series and Review of the Literature by Ikediobi, Ogechi, Schneider, Jeremy A

    Published in Journal of personalized medicine (26-01-2021)
    “…Severe cutaneous adverse drug reactions (SCAR) such as the Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug rash with eosinophilia and…”
    Get full text
    Journal Article
  13. 13
  14. 14

    CYP2B66 and CYP2B618 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women by Röhrich, Carola R, Drögemöller, Britt I, Ikediobi, Ogechi, van der Merwe, Lize, Grobbelaar, Nelis, Wright, Galen E B, McGregor, Nathaniel, Warnich, Louise

    Published in AIDS research and human retroviruses (01-06-2016)
    “…Long-term exposure to efavirenz (EFV) measured in hair samples may predict response to antiretroviral treatment (ART). Polymorphisms in CYP2B6 are known to…”
    Get more information
    Journal Article
  15. 15
  16. 16

    Addressing the Challenges of the Clinical Application of Pharmacogenetic Testing by Ikediobi, ON, Shin, J, Nussbaum, RL, Phillips, KA, Walsh, JM, Ladabaum, U, Marshall, D

    Published in Clinical pharmacology and therapeutics (01-07-2009)
    “…Pharmacogenomics aims to use molecular genetic markers to predict treatment outcome. Indeed, within the past decade there has been a rapid emergence of…”
    Get full text
    Journal Article
  17. 17

    Multifactorial regulation of E-cadherin expression: an integrative study by Reinhold, William C, Reimers, Mark A, Lorenzi, Philip, Ho, Jennifer, Shankavaram, Uma T, Ziegler, Micah S, Bussey, Kimberly J, Nishizuka, Satoshi, Ikediobi, Ogechi, Pommier, Yves G, Weinstein, John N

    Published in Molecular cancer therapeutics (01-01-2010)
    “…E-cadherin (E-cad) is an adhesion molecule associated with tumor invasion and metastasis. Its down-regulation is associated with poor prognosis for many…”
    Get full text
    Journal Article
  18. 18

    Pharmacogenomic Applications in Oncology by Walko, Christine M., Ikediobi, Ogechi

    Published in Journal of pharmacy practice (01-08-2012)
    “…Oncology chemotherapeutics frequently exhibit a narrow therapeutic index, further complicated by the serious nature of dosing either too high (dangerous…”
    Get full text
    Journal Article
  19. 19

    Long-circulating monensin nanoparticles for the potentiation of immunotoxin and anticancer drugs by Shaik, Madhu Sudhan, Ikediobi, Ogechi, Turnage, Valerie D., McSween, Jelino, Kanikkannan, Narayanasamy, Singh, Mandip

    Published in Journal of pharmacy and pharmacology (01-05-2001)
    “…The carboxylic ionophore monensin was formulated into long‐circulating nanoparticles with the help of polyethylene glycol/poly (dl‐lactide‐co‐glycolide)…”
    Get full text
    Journal Article
  20. 20